Abstract
The greater sensitivity of cancer cells to heat compared to healthy cells allows to destroy or make them more susceptible to treatment, using hyperthermia. Hyperthermia has been clinically used as an adjuvant therapy. Its limitations as a single therapy relate to the lack of dosimetry for clinical protocols, balancing between safety and efficacy, and the absence of homogenous heating surrounding cancer cells. Magnetic hyperthermia has been applied safely, offering a penetration depth that allows the induction of local heat in inner body tissues, while the use of magnetic nanoparticles, particularly Iron Oxide Nanoparticles (IONPs), allows for selective heating via the Enhanced Permeability and Retention (EPR) effect for tumor accumulation. The Sarah Nanotechnology system offers novel IONPs that heat in a magnetic field, with self-regulating temperature and a standardized protocol up scalable from animal models to human, thus overcoming the safety challenges of standard hyperthermia in addition to providing high efficacy.
Keywords:Magnetic Hyperthermia; Iron Oxide Nanoparticles; Alternating Magnetic Field; Cancer; Enhanced Permeability and Retention Effect.
Abbreviations: EPR: Enhanced Permeability and Retention, IONPs: Iron Oxide Nanoparticles, RF: Radio Frequency, MRI: Magnetic Resonance Imaging, SCLC: Small Cell Lung Cancer, AC: Alternating Current
Mini Review
Hyperthermia has been defined as the process of increasing
the temperature of the body or a particular region of it beyond the
threshold level set at a particular moment by the thermoregulatory
system of an organism [1]. The stage of the cancer, the locations
of malignancies and their depths inside the body, play a role
when choosing the appropriate method of clinical hyperthermia
application out of the existing three standard options: whole-body,
regional, or local hyperthermia. While whole-body heat application
is used to treat deep seated and disseminated malignancies, local
or regional treatments deliver heat to localized or advanced cancer,
respectively [2]. During the last decades, hyperthermia has been
only used in combination with radiotherapy or chemotherapy
mainly due to operational constraints and the incidence of harmful
secondary effects that were found to affect the surrounding healthy
tissues [3,4].
Some thermal damage, such as the appearance of burns on
external tissue, is a common side effect of treatment. This can be
avoided by maximizing toxic effects on the tumor area and confining
the heating to the volume of the tumor mass [1]. In addition
to thermal damage, transient adverse effects such as vomiting,
diarrhea, and nausea may appear. On rare and extreme occasions
cardiac, vasculature and cerebral disorders may arise [5,6]. Since
these occurrences are highly uncommon, and the ability to control,
monitor, and understand hyperthermia and its effects has increased
over recent years, its side effects are generally considered to be not
serious, especially in comparison to other cancer treatments [5].
Several studies testing the clinical benefits of hyperthermia have
been performed, providing evidence that hyperthermia is less
efficacious when applied as a single therapy, with limiting factors
such as the reproducibility of heat deposition into the tumor mass,
the formation of hotspots [4,7], and the challenging measurement
of the temperature within the tumor and its vicinity.
Nevertheless, hyperthermia has been demonstrated in trials
to prolong life and decrease disease re-appraisal as an adjuvant
therapy, damaging cancer cells and causing radiation and chemosensitization,
with some tumors being more responsive than others [4]. Magnetic hyperthermia is based on the use of magnetic
nanoparticles to induce local heat when a Radiofrequency (RF)
magnetic field is applied, thereby providing an effective approach
to destroy cancer cells [3]. Experimental studies examining the
application of magnetic materials for hyperthermia date back
to 1957 when Gilchrist et al. [8] heated various tissue samples
using magnetic IONPs with a size of 20-100nm, exposed to a
1.2MHz magnetic field, resulting in selective heating of lymphatic
metastases. Henceforth, there have been several publications
describing a variety of settings employing different types of
magnetic nanoparticles, methods of encapsulation and delivery,
and field strengths and frequencies [9].
Magnetic nanoparticles have demonstrated a wide range of
applications including cell labelling and magnetic separation which
is applied to many aspects of biomedical and biological research,
use as contrast agents in Magnetic Resonance Imaging (MRI),
targeted drug delivery, and hyperthermia-based cancer treatment
[9]. The electromagnetic radiation used in magnetic hyperthermia
is within the RF range (between several kHz and MHz). This
radiation shows enough penetration depth to access inner organs
or tissues in the body and is relatively safe. The specificity of this
technique is achieved by the higher sensitivity of cancer cells
to temperature increases above 42°C. The majority of cancer
cells tend to die between 40°C and 43°C [10]. When cancer cells
are subjected to this temperature range, they suffer irreversible
damage, in a time and dose dependent manner, which includes
changes in several biochemical processes that include, inhibition
of DNA and RNA synthesis, DNA repair mechanisms, alterations in
membrane fluidity, mitochondria structure, enhanced production
of heat shock proteins that can affect thermotolerance and tumor
immunogenicity, increased influx of reactive oxygen radicals, and
others [10].
Because of the results that high temperature may produce in
tissues, the use of temperatures above 50°C can be referred to as
coagulation, and between 60°C to 90°C as thermal ablation [11].
Several studies have demonstrated the therapeutic efficacy of
magnetic hyperthermia in clinical trials [12] and animal models [13].
The challenge is how to deliver a sufficient amount of the magnetic
particles to generate enough heat in the target using Alternating
Current (AC) magnetic field conditions that are clinically acceptable
and could be safely used in human patients. For example, a study in
swine [14] reported the repeated use of the Kanzius non-invasive
RF hyperthermia system (KNiRFH) which operates at 13.56MHz, to
treat liver cancer via targeted heating of tumors. Blood tests, MRI
and specific absorption rates (SAR) level of the liver and fat were
calculated to determine the system’s heating efficacy and potential
toxicities. No indications of aberrations, damage or toxicity were
identified.
On the other hand, at 38.5°C, liver hyperthermia was not achieved,
once again demonstrating the difficulty to generate significant and homogenous local heating, in the absence of nanoparticles. The
Sarah Nanotechnology System, developed by New Phase Ltd., is
a medical device designed to treat metastatic stage IV Small Cell
Lung Cancer (SCLC) and solid tumors through the delivery of
thermal energy to malignant cells, thereby causing hyperthermiainduced
cancer cell death at sub-ablative temperatures of up to
50°C. The system involves two main components: (1) multicore
Sarah Nanoparticles (SaNPs) containing encapsulated iron oxide
and (2) an Electromagnetic Induction System (EIS). The SaNPs are
administered intravenously to the patient and become localized
via the EPR effect on cancer cells, which allows extravasation of
the nanoparticles and enables the preferential retention of SaNPs
in tumors due to their leaky vasculature and reduced lymphatic
drainage [15].
Following delivery and accumulation of SaNPs on the malignant
tissue, the patient undergoes regional AC magnetic field (AMF)
application at 290±10% kHz. The SaNPs absorb the RF power
and convert it to thermal energy, reaching a pre-determined
temperature (50±3°C), thereby heating the malignant cells and
causing hyperthermic cancer cell death without harming healthy
cells. The SaNP has an inherent ability that is both novel and unique
to regulate its own temperature, preventing the occurrence of
thermal ablation. The efficacy of Sarah Nanotechnology treatment
has been extensively evaluated by New Phase in pre-clinical studies,
using the murine 4T1 breast cancer metastatic model in BALB/c
mice. Several studies were conducted to determine the optimal
conditions required for efficacy testing including, time intervals
and exposure times for effective AMF application following SaNP
administration. These studies have demonstrated a significant
reduction in the number of lung metastases, their size and viability
(data submitted for publication) suggesting that an adequate
quantity of SaNP reaches the target organ and generates a sufficient
thermal mass required to induce thermal damage to the cancerous
tissue.
Phase I clinical reports have confirmed that the use of AMF
is safe enough for clinical use, although optimization for the best
clinical results is still needed. Johannsen et al. [16], have initially
demonstrated the clinical use of hyperthermia for prostate cancer
treatment and localized heating of prostate tumors following
direct injection of magnetic nanoparticles with a size of 1-100nm
and an AMF applicator (MagForce Nanotechnologies) operating
at 100kHz. Maximum temperatures of up to 55°C were achieved
in the prostate. Two separate phase I studies, with and without
brachytherapy, were conducted showing feasibility and good
tolerability. Throughout the history of hyperthermia, a major issue
has been the lack of a uniform dosimetry protocol. A thermal dose
of CEM 43°C T90 (cumulative equivalent minutes at a standard
targeted treatment temperature of 43°C obtained within 90% of
the tumor volume) was found to be the most useful dosimetric
parameter in clinical research, suggested as a treatment goal.
This can be explained by the fact that cumulative delivering
of at least 43°C to 90% of a tumor’s volume for ≥10 minutes
corresponds to doubling of the probability for complete response
and duration of response to hyperthermia [11]. Biodistribution and
toxicity studies in murine and swine models, conducted by New
Phase, have shown that in swine, SaNPs consistently accumulate
also in the lungs, the target organ. The operation protocol of the
EIS machine has been set to work at the same frequency (290±10%
kHz) using 10 minutes intervals of discontinuous irradiation in both
small and large animals. The same setup will be used in a first-inhuman
clinical trial. New Phase has been able to upscale the dosing
regimen from mice, to swine, and to humans in accordance with the
FDA guideline for the estimation of the maximum safe starting dose
in initial clinical trials for therapeutics in healthy human subjects
[17].
Dose calculation was based on the no observed adverse effect
level (NOAEL) principle for dosage scaling from animal to human or
from animal to animal. No deleterious effects have been observed,
even at high doses of 156% in swine (manuscript in preparation),
and SaNP accumulation in healthy tissues does not induce any
undesirable side or toxic effects and no thermal damage has
been observed after whole-body (mice) or regional (swine) AMF
application, with the SaNPs undergoing normal physiological
excretion over time. The Sarah Nanotechnology uses a standardized
protocol, up-scalable from mice to swine, to create a RF penetrative
field that heats SaNPs, resulting in the localized, selective heating
of cancer tissues, with results indicative of high safety and efficacy.
Combined with the SaNP’s distinct control of its temperature, the
Sarah Nanotechnology overcomes many of the issues associated
with hyperthermia and can be considered a potential novel
therapeutic modality for cancer patients.
References
- Dewhirst MW, Gibbs FA, Roemer RB, Samulski TV (2000) Hyperthermia. In: Gunderson LL, Tepper JE (eds.). Clin. Rad. Oncol. 1st edn Chapter 14. New York, NY: Churchill Livingstone pp. 256-82.
- Behrouzkia Z, Joveini Z, Keshavarzi B, Eyvazzadeh N, Aghdam RZ (2016) Hyperthermia: How can it be used? OMJ 31(2): 89-97.
- Bañobre López M, Teijeiro A, Rivas J (2013) Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep. Pract. Oncol. Radiother 18(6): 397-400.
- Baronzio G, Parmar G, Ballerini M, Szasz A, Baronzio M, et al. (2014) A brief overview of hyperthermia in cancer treatment. J Integr Oncol 3(1): 115.
- Jha S, Sharma PK, Malviya R (2016) Hyperthermia: Role and risk factor for cancer treatment. Achieve Life Sci 10(2): 161-167.
- Walter E, Carraretto M (2015) Getting hot and bothere. J Intensive Care Soc 16(3): 189-192.
- Chatterjee DK, Diagaradjane P, Krishnan S (2011) Nanoparticle-mediated hyperthermia in cancer therapy. Ther Deliv 2(8): 1001-1014.
- Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, et al. (1957) Selective inductive heating of lymph nodes Ann. Surg 146: 596-606.
- Pankhurst QA, Connolly J, Jones SK, Dobson J (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 36: R167-R181.
- Pietrangeli P, Mondovì B (2006) On the biochemical basis of tumor damage by hyperthermia. In: Hyperthermia in cancer treatment: a primer. Gianfranco Baronzio and E Dieter Hager (Eds), Landes BioScience.
- Chicheł A, Skowronek J, Kubaszewska M, Kanikowski M (2007) Hyperthermia-description of a method and a review of clinical applications. Rep Pract Oncol Radiother 12(5): 267-275.
- Liu X, Zhang Y, Wang Y, Zhu W, Li G, et al. (2020) Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy. Theranostics 10(8): 3793-3815.
- Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 18(4): 267-284.
- Ho JC, Nguyen L, Law JJ, Ware MJ, Keshishian V, et al. (2017) Non-invasive radiofrequency field treatment to produce hepatic hyperthermia: Efficacy and safety in swine. IEEE J Transl Eng Health Med 5: 1500109.
- Abdalla AME, Xiao L, Ullah MW, Yu M, Ouyang C, et al. (2018) Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics. Theranostics 8(2): 533-548.
- Johannsen M, Thiesen B, Wust P, A Jordan (2010) Magnetic nanoparticle hyperthermia for prostate cancer. Int. J. Hyperthermia 26(8): 790-795.
- (2005) USFDA. Guidance for Industry: Estimating the maximum safe starting dose in adult healthy volunteers. Rockville, MD: US Food and Drug Administration.